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Changes in severity, mortality, 
and virus genome among a Spanish 
cohort of patients hospitalized 
with SARS‑CoV‑2
Rocío Aznar‑Gimeno1,12*, J. Ramón Paño‑Pardo2,3,4,12*, Luis M. Esteban5, 
Gorka Labata‑Lezaun1, M. José Esquillor‑Rodrigo6, Angel Lanas3,4,7,8, David Abadía‑Gallego1, 
Francisco Diez‑Fuertes9,10, Carlos Tellería‑Orriols11, Rafael del‑Hoyo‑Alonso1,13 & 
M. Trinidad Serrano3,4,7,13
Comparing pandemic waves could aid in understanding the evolution of COVID‑19. The objective 
of the present study was to compare the characteristics and outcomes of patients hospitalized 
for COVID‑19 in different pandemic waves in terms of severity and mortality. We performed an 
observational retrospective cohort study of 5,220 patients hospitalized with SARS‑CoV‑2 infection 
from February to September 2020 in Aragon, Spain. We compared ICU admissions and 30‑day 
mortality, clinical characteristics, and risk factors of the first and second waves of COVID‑19. The 
SARS‑CoV‑2 genome was also analyzed in 236 samples. Patients in the first wave (n = 2,547) were 
older (median age 74 years [IQR 60–86] vs. 70 years [53–85]; p < 0.001) and had worse clinical and 
analytical parameters related to severe COVID‑19 than patients in the second wave (n = 2,673). The 
probability of ICU admission at 30 days was 16% and 10% (p < 0.001) and the cumulative 30‑day 
mortality rates 38% and 32% in the first and second wave, respectively (p = 0.007). Survival differences 
were observed among patients aged 60 to 80 years. We also found some variability among death risk 
factors and the viral genome between waves. Therefore, the two analyzed COVID‑19 pandemic waves 
were different in terms of disease severity and mortality.
COVID-19, caused by SARS-CoV-2, is the first major pandemic humankind has faced in over 100 years. Pursu-
ing naturally acquired herd immunity is not a feasible  strategy1. In contrast to SARS-CoV-1, the transmission 
of SARS-CoV-2 is expected to resemble that of pandemic influenza, with several pandemic waves, followed by 
seasonal circulation as may have previously happened with other known  coronaviruses2,3. We do not yet know 
how far this virus will continue to be transmitted. The emergence of specific, highly effective vaccines offers hope 
for the  future4–7, but only universal vaccination will prevent further outbreaks.
Although there have been different pandemic waves, no extensive studies have analyzed whether the severity 
and mortality are similar, or whether there are variations depending on the different situations in which they 
arise.
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Aragón is an autonomous Spanish community that experienced the first pandemic wave between February 
and May 2020. After a period of full lockdown, community transmission of SARS-CoV-2 decreased  markedly8. 
After several local outbreaks in June and July, SARS-CoV-2 transmission was widespread, and Aragón had 
the highest midsummer incidence in the European  region9,10. Although there are indications that the second 
wave was less severe than the  first11, data supporting this hypothesis are scarce. Similarly, although studies have 
identified risk factors for disease  severity12, studies comparing the evolution of hospitalized patients in terms of 
severity and mortality are lacking.
The present study compared the two first different pandemic waves in terms of severity and mortality (ICU 
admission and death) among hospitalized patients with COVID-19 and analyzed the characteristics of the 
affected population and risk factors for severity. This knowledge can help us understand the behavior of this 
disease over time.
Methods
Design and setting. This is an observational retrospective cohort study that includes all patients hospital-
ized with COVID-19 in Aragon, a region in Northeastern Spain that comprises 1,328,753 inhabitants (January 
1, 2020) with a highly centralized distribution; 52.7% of the population lives in one city. The publicly funded 
healthcare system (SALUD) covers the entire population of the region via seven hospitals. Two of these hospitals 
are university hospitals with more than 700 beds, and the rest are regional hospitals.
The research protocol was approved by the Clinical Research Ethics Committee of Aragon (PI 20/183) accord-
ing to good clinical practices and applicable laws and regulations. Due to the retrospective, observational nature 
of this study, the data could be fully anonymized and informed consent was waived. All methods were performed 
in accordance with the relevant guidelines and regulations.
Patients and data acquisition. Our primary data source was the Aragón Healthcare Records Database, 
which we accessed through the BIGAN Gestion Clinica platform of the Aragón Department of Health. This data-
base contains demographic and clinical information on all individuals covered by SALUD.
COVID-19 diagnosis was confirmed by positive SARS-CoV-2 RT-PCR. Laboratory-confirmed COVID-
19-associated hospitalizations were identified using laboratory and electronic medical records databases. Hos-
pitalization was considered chronologically related to COVID-19 when it occurred within the first 20 days after 
or no more than 10 days before the first positive SARS-CoV-2 PCR test.
Data were extracted for a total of 5,220 patients with SARS-CoV-2 infection who were hospitalized in the 
SALUD hospital network between February 27, 2020, and September 23, 2020.
The criteria for admission and hospital management of patients with SARS-Cov-2 infection are based on the 
recommendations contained in the technical document published by Spanish Ministry of Health. The document 
includes Covid-19 emergency management and Covid-19 clinical management: hospital care13. Each hospital has its 
own protocol adapting these recommendations to its characteristics. The information is available at the websites 
for each hospital. The hospitalization and ICU admission criteria, according to these guidelines, have remained 
stable throughout the pandemic. Ultimately, however, clinical decisions may vary at the discretion of practitioner.
The beginning and end of each wave was defined based on the variation in SARS-CoV-2 infection incidence 
observed from February 27 to September 23. We observed two well-defined waves: the first from February 27 
to May 27, 2020, and the second from June 17 to September 23, 2020 (Fig. 1). However, by September 23, the 
second wave has not fully declined.
We collected data on patient demographics, comorbidities, and drugs prescribed in the 6 months prior to 
hospitalization, Vital signs were recorded upon arrival at the emergency room for all patients, Laboratory vari-
ables measured in the first 24 h were available only for the largest two hospitals in the SALUD network, which 
represented 60.6% of all patients admitted with COVID-19 in the region. The observation period lasted up to 
30 days after the last patient was included in the analysis. The main outcomes were admission into the intensive 
care unit (ICU) and 30-day all-cause mortality after hospital admission.
The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines for cohort  studies14.
Statistical analysis. Our study compared four main topics between the two waves: descriptive variables, 
mortality risk factors, severity and mortality (longitudinal analysis), and the viral genome.
Descriptive analysis. We performed a comparative descriptive analysis of the first- and second-wave cohorts 
stratified by hospitalized, ICU admission, and death. Previously, normality was tested using the Shapiro–Wilk 
test. As continuous variables failed the normal distribution, they are presented as the median and interquartile 
range (IQR), and categorical variables are presented as absolute and relative frequencies. Comparisons were 
performed using the Mann–Whitney test for continuous variables and chi-squared test for categorical variables 
or proportions.
Identification of mortality risk factors. We analyzed univariate logistic regression models to identify predictors 
of death in each of the subcohorts. To better identify the truly significant predictors in the univariate analysis, 
not based only on an extensive search, we estimated the adjusted p-values for multiple comparisons using the 
Holm  method15.
Multivariate analysis provides additional information about which of these predictors are independent risk 
factors. To analyze the difference between waves, we have defined a new dichotomical categorical variable that 
distinguish between waves. Logistic regression model has been constructed taking as candidates not only the 
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18844  | https://doi.org/10.1038/s41598-021-98308-x
www.nature.com/scientificreports/
predictor variables, but also their interaction with the variable defining the wave Thus, if the interaction term is 
statistically significant we can affirm that we found differences for this predictor variable between waves.
The discriminatory capacities of univariate significant risk factors were evaluated by measuring the area under 
the receiver operating characteristic (ROC) curve (AUC). Results are expressed as odds ratios (ORs) and p-values.
Longitudinal analysis of severity and mortality. Two longitudinal analyses were performed in the cohort of 
hospitalized patients to evaluate the management of ICU admission and occurrence of death in the two waves. 
The follow-up time started from the hospitalization date and ended at either the ICU admission date or the dis-
charge/death date. We used cumulative incidence curves to analyze the longitudinal data, and the Gray test to 
compare variables between waves for groups stratified by sex or age.
The threshold p-value was set at 0.05. Analyses were performed using R version 3.6.2 language programming 
(R Foundation for Statistical Computing, Vienna, Austria) and Python version 3.7 provided by Jupyter (jupyter.
org). R statistical software was used mainly for statistical analysis and Python for data retrieval and preparation.
Viral genome analysis. Whole genome sequences (> 29,000 bp) of SARS-CoV-2 from Aragon (n = 295) were 
retrieved from the database established by the global initiative on sharing all influenza data (GISAID). We evalu-
ated how these sequences were distributed among different phylogenetic clades. Sequences were aligned by 
an iterative refinement method implemented in MAFFT version 7  software16 and manually edited in Bioedit 
v7.2.517. The phylogeny of the alignment was inferred with IQ-Tree software v2.1.118, and node support was 
assessed by an ultrafast bootstrap approximation. The TIM2 substitution model, with unequal base frequencies 
and a proportion of invariant sites (TIM2 + F + I), was selected as the best-fit model according to the Bayesian 
information criterion. In Aragón, the prevalence of the D614G mutation was tracked throughout the pandemic 
by aligning this region in all 295 genomes.
Results
Descriptive analysis. The patient flowchart is given in Fig. 2. A total of 2,547 patients were hospitalized 
with SARS-CoV-2 infection in the first wave and 2,673 in the second wave. Of these patients, 332 (13%) and 198 
(7.4%) were admitted to the ICU (p < 0.001), and 779 (30.6%) and 501 (18.7%) died (p < 0.001) during the first 
and second waves, respectively. The cumulative cases between waves are compared in Fig. 3.
The age and sex distributions of patients who were hospitalized, admitted to the ICU, or deceased are shown 
for both waves in Fig. 4. In both waves, a higher proportion of men were hospitalized with COVID-19 compared 
to women. This difference increased in the population admitted to the ICU, but not in regards to mortality. 
Figure 1.  Hospitalized patients with positive SARS-Co V-2 RT-PCR test results in both pandemic waves in 
Aragon, Spain, February-September 2020. Blue: first wave; green: second wave.
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However, for each of these subpopulations (hospitalized, ICU admission, death), the sex distribution was not 
significantly different between waves (p > 0.927).
Among all patients hospitalized with COVID-19, the mean age was significantly different between the two 
waves (Table 1). Patients in the first wave were older (median 74 years, [IQR 60–86] vs. 70 years [53–85]; 
p < 0.001) and had more comorbidities, including cerebrovascular disease and dementia, as well as previous 
pneumonia than patients in the second wave. However, the second wave had a higher frequency of diabetes. In 
addition, previous drug treatments in hospitalized patients differed between the two pandemic waves.
Compared to the second wave, patients hospitalized in the first wave showed signs of greater disease sever-
ity, including a higher heart rate, higher temperature, lower oxygen saturation, and higher levels of creatinine, 
Figure 2.  Selection and analysis of study participants in Aragon, Spain, February-September 2020.
Figure 3.  Comparison of cumulative cases between pandemic waves in Aragon, Spain, February-September 
2020. Prevalence of SARS-CoV-2 cases confirmed by RT-PCR during the first (purple) and second waves (green) 
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Figure 4.  Sex and age distributions of patients who tested positive for COVID-19 during the two pandemic 
waves in Aragon, Spain, February-September 2020. ICU: intensive care unit. Top: Hospitalized patients; Middle: 
patients admitted to ICU; Bottom: patients who died. Blue: males; red: females.
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Variable
Hospitalized patients ICU patients Deaths













256 (51.1) 245 
(48.9) 0.207
Age (y) 74 (60–86) 70 (53–85)  < 0.001 70 (60–76) 62 (54–72)  < 0.001 85 (77–90) 87 (81–91) 0.011
Emergency room
Systolic pressure 
(mm Hg) 126 (112–141) 128 (114–142) 0.126 127 (114–143) 130 (115–144) 0.319 122 (108–141) 129 (113–145) 0.008
Diastolic pressure 
(mm Hg) 71 (62–80) 72 (64–80) 0.111 73 (63–81) 73.5 (66–81) 0.210 68 (59–78) 69 (61–78) 0.298
Heart rate (bpm) 86 (75–98) 83 (73–97) 0.001 90 (78–101) 88 (77–100) 0.265 87 (74–100) 85 (73–98) 0.183
Respiratory rate 
(bpm) 25 (20–32) 26 (22–32) 0.487 26 (20.5–32 ) 27.5 (23.7–32) 0.329 30 (24–34) 31 (24–36) 0.194
Temperature (ªC) 36.8 (36.3–37.5) 36.6 (36.2–37)  < 0.001 37 (3.5–37.8 ) 36.7 (36.3–37.3) 0.001 36.9 (36.3–37.5) 36.6 (36.3–37.2) 0.001
Oxygen saturation 
(%) 95 (92–97) 95 (93–97)  < 0.001 94 (90–97) 94 (92–96) 0.374 94 (90–96) 94 (92–96) 0.004
Oxygen treatment 
(%) 278 (12.7) 239 (9.6) 0.001 41 (13.7) 18 (10) 0.262 75 (11.9) 50 (10.5) 0.499
Capillary blood 
glucose (mg/dl) 147 (118–194) 150 (121–215) 0.329 147 (117.7–195.5) 151 (126–210) 0.590 162 (124.5–218) 180 (140–255) 0.056
Laboratory
Glucose (mg/dl) 113 (97–139) 116 (97–144) 0.434 156.5 (117–211) 164 (123–203) 0.481 123 (101–164) 132 (104–172) 0.105
Creatinine (mg/dl) 0.94 (0.74–1.29) 0.89 (0.69–1.19)  < 0.001 0.93 (0.71–1.31) 0.73 (0.58–0.99)  < 0.001 1.22 (0.91–1.86) 1.18 (0.84–1.64) 0.091
Urea (g/l) 0.421 (0.3–0.69) 0.4 (0.29–0.62) 0.003 0.51 (0.36–0.74) 0.47 (0.34–0.62) 0.123 0.71 (0.5–1.06) 0.63 (0.43–0.94) 0.014
Chloride (mmol/l) 101 (98–105) 102 (99–105) 0.032 103 (99–106) 104 (102–107)  < 0.001 103 (99–107) 102 (99–106) 0.412
Potassium (mmol/l) 4.17 (3.84–4.53) 4.19 (3.86–4.52) 0.904 4.14 (3.77–4.59) 4.11 (3.85–4.41) 0.561 4.31 (3.84–4.68) 4.25 (3.83–4.59) 0.241
Ionic Calcium 








33 (24–49.75) 32 (23–47) 0.235 47 (31–74.5) 38 (27–54) 0.004 35 (23–53) 34 (24–49) 0.610
Lactate dehydroge-
nase (LDH) (U/l) 292 (230–398 ) 286 (224–372 ) 0.018 465 (345–600 ) 438 (332–546) 0.247 319 (244–439) 310 (238–458) 0.609
Prothrombin activ-










1 (0.91–1.1) 0.97 (0.89–1.06)  < 0.001 0.97 (0.9–1.08) 0.91 (0.83–0.99)  < 0.001 1.01 (0.92–1.11) 0.97 (0.89–1.08) 0.003
D-Dimer 
(microgr/l) 958 (519–1770) 758 (428–1431)  < 0.001 1334 (808–2418) 1129 (612–2567) 0.310 1495 (972–3603) 1327 (772–3893) 0.139
Fibrinogen (mg/dl) 700 (599–709) 657 (550–700)  < 0.000 700 (657–847) 700 (577–764) 0.004 680 (571–715) 650 (531–700) 0.008
Leukocytes (mil/
mm3) 6.8 (5.1–9.3) 6.64 (4.9–9) 0.055 9 (6.77–12.1) 9.6 (7.05–12.5) 0.276 8 (5.8–10.95) 7.55 (5.3–10.3) 0.099
Lymphocytes (mil/
mm3) 0.95 (0.67–1.38) 1.02 (0.70–1.48) 0.001 0.64 (0.44–0.94) 0.68 (0.46–0.96) 0.279 0.81 (0.53–1.26) 0.77 (0.56–1.10) 0.374
Lymphocytes % 14.6 (8.7–22.6) 16.4 (9.9–24.5)  < 0.001 7.1 (4.4–12.0) 6.9 (4.5–11.9) 0.787 10.1 (6–17.4) 10.7 (6.3–18.0) 0.684
Monocytes (mil/
mm3) 0.50 (0.35–0.68) 0.49 (0.34–0.70) 0.530 0.41 (0.27–0.64) 0.51 (0.34–0.72) 0.010 0.51 (0.34–0.73) 0.48 (0.31–0.69) 0.098
Monocytes % 7.6 (5.3–9.99) 7.6 (5.3–10.1) 0.636 4.8 (3.2–7.015) 5.3 (3.8–7.45) 0.158 6.4 (4.2–9.4) 6.365 (4.1–9.2) 0.396
Neutrophils (mil/
mm3) 5.00 (3.46–7.39) 4.82 (3.24–6.99) 0.011 7.91 (5.48–10.7) 8.16 (5.77–10.9) 0.548 6.19 (4.25–9.33) 6.07 (3.83–8.67) 0.337
Neutrophils % 76 (66.6–84.4) 74.1 (64.8–82.9)  < 0.001 88.2 (80.2–91.2) 86.6 (80.3–91.1) 0.348 81.7 (72.8–88) 81.6 (72.3–89) 0.798
Basophils (mil/
mm3) 0.02 (0.01–0.03) 0.02 (0.01–0.03) 0.423 0.02 (0.01–0.03) 0.01 (0.00–0.03) 0.001 0.02 (0.01–0.04) 0.02 (0.01–0.03) 0.162
Basophils % 0.3 (0.2–0.5) 0.3 (0.2–0.5) 0.776 0.2 (0.1–0.3) 0.1 (0.1–0.2)  < 0.001 0.265 (0.1–0.4) 0.27 (0.1–0.4) 0.460
Eosinophils (mil/
mm3) 0.007 (0–0.036) 0.008 (0–0.039 ) 0.471 0 (0–0.016 ) 0 (0–0) 0.004 0.002 (0–0.021) 0.001 (0–0.016 ) 0.478
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Variable
Hospitalized patients ICU patients Deaths
First wave Second wave p-value First wave Second wave p-value First wave Second wave p-value
Red blood cells 
(mil/mm3) 4.52 (4.08–4.87) 4.52 (4.09–4.91) 0.281 4.17 (3.79–4.52) 4.24 (3.80–4.59) 0.280 4.31 (3.84–4.70) 4.34 (3.84–4.72) 0.585
Erythroblasts (mil/
mm3) 0.001 (0–0.009) 0.002 (0–0.01) 0.088 0.001 (0–0.01) 0 (0–0.01) 0.695 0.001 (0–0.01 ) 0.002 (0–0.01) 0.456





33.4 (32.8–34 ) 33.5 (32.9–34.1) 0.022 33.4 (33.0–34.1) 33.5 (33.0–34.1) 0.327 33.1 (32.6–33.7) 33.1 (32.5–33.6) 0.786
Hemoglobin (g/dl) 13.5 (12.3–14.6) 13.6 (12.3–14.7) 0.554 12.6 (11.3–13.7) 12.8 (11.5–1..8) 0.367 13 (11.7–14.2) 1.1 (11.8–14.3) 0.379
Hematocrit (%) 40.4 (36.9–43.5) 40.4 (36.9–43.7) 0.893 37.6 (34.1–40.4) 37.7 (34.6–40.9) 0.392 39.2 (35.4–42.8) 39.4 (35.8–43.1) 0.422
Mean corpuscular 
volume (MCV) (fl) 90.3 (86.6–93.6) 90 (86.15–93.6) 0.158 90.2 (87.6–93.3) 90.4 (86–93.8) 0.701 91.8 (87.7–95.3) 92.2 (88.5–95.6) 0.413
Platelet count (mil/
mm3) 188 (143–246) 190 (148–246) 0.610 227 (169–288) 242 (173–312) 0.334 177 (136–230) 172 (131–215) 0.246
Mean platelet vol-
ume (MPV) (fl) 9.1 (8.4–9.9) 9.2 (8.5–9.9) 0.197 8.9 (8.275–9.7) 8.9 (8.3–9.6) 0.881 9.2 (8.7–10.2 ) 9.4 (8.6–10.1) 0.688
Interleukin-6 (pg/
ml) 41.51 (17.18–50) 32.5 (12.6–58.6) 0.161 50 (21.5–82.2) 50 (16.9–94.4) 0.825 50 (36.3–84.2) 50 (25.9–102.2) 0.830
C-reactive protein 
(mg/l) 8.18 (2.75–15.07) 5.52 (1.64–11.23)  < 0.001 14.56 (5.9–24.61) 8.31 (2.44–15.5) 0.001 11.15 (5.52–1.8) 9.69 (2.48–17.52) 0.065
Procalcitonin 
(mg/l) 0.13 (0.07–0.32) 0.11 (0.07–0.24) 0.084 0.36 (0.16–0.94) 0.17 (0.09–0.57)  < 0.001 0.24 (0.13–0.73) 0.24 (0.12–0.59) 0.662
Ferritin (ng/ml) 452 (220–1003) 614 (306–1190) 0.007 1277 (583–2727) 1145 (659–2026) 0.971 460 (216–997) 704 (360–1268) 0.054
Comorbidities/Previous diagnosis
Ischemic Cardi-
opathy 207 (8.1) 180 (6.7) 0.054 27 (8.1) 17 (8.6) 0.880 95 (12.2) 62 (12.4) 0.932
Hypertension 835 (38.2) 877 (35.3) 0.050 115 (38.5) 56 (31.1) 0.108 319 (50.6) 234 (49.1) 0.631
Intermittent clau-
dication 109 (4.3) 97 (3.6) 0.261 19 (5.7) 10 (5.1) 0.854 66 (8.5) 24 (4.8) 0.014
Cerebrovascular 
disease 292 (11.5) 248 (9.3) 0.013 21 (6.3) 11 (5.6) 0.841 156 (20.0) 106 (11.2) 0.663
Dementia 354 (13.9) 279 (10.4)  < 0.001 21 (6.3) 2 (1.0) 0.002 200 (25.7) 125 (24.9) 0.802
Diabetes 493 (19.4) 588 (22.0) 0.018 72 (21.7) 56 (28.3) 0.096 198 (25.4) 147 (29.3) 0.150




367 (14.4) 375 (14.0) 0.717 52 (15.7) 31 (15.7) 1.000 137 (17.6) 96 (19.2) 0.506
Previous pneu-
monia 381 (15.0) 230 (8.6)  < 0.001 76 (22.9) 20 (10.1)  < 0.001 117 (15.0) 47 (9.4) 0.004
Malignancy 132 (5.2) 124 (4.6) 0.362 16 (4.8) 8 (4.0) 0.824 57 (7.3) 32 (6.4) 0.587
Previous Treatment
Gastric secretion 
inhibitors 1045 (41) 970 (36.3)  < 0.001 124 (37.3) 72 (36.4) 0.856 454 (58.3) 273 (54.5) 0.187
Antidiabetics 408 (16) 471 (17.6) 0.128 61 (18.4) 56 (28.3) 0.008 164 (21.1) 114 (22.7) 0.479
Antithrombotics 739 (29) 688 (25.7) 0.007 78 (23.5) 43 (21.7) 0.669 359 (46.1) 219 (43.7) 0.431
Beta-blockers 400 (15.7) 364 (13.6) 0.034 55 (16.6) 27 (15.6) 0.367 177 (22.7) 105 (21) 0.466
Potassium-sparing 
diuretics 115 (4.5) 94 (3.5) 0.07 9 (2.7) 5 (2.5) 1.000 61 (7.8) 20 (4) 0.007
Anxiolytics 276 (10.8) 237 (8.9) 0.019 46 (13.9) 23 (11.6) 0.511 184 (23.6) 102 (20.4) 0.200
Antidementia 
drugs 41 (1.6) 37 (1.4) 0.559 11 (3.3) 1 (0.5) 0.057 88 (11.3) 68 (13.6) 0.262
Nutritional supple-
ments 194 (7.6) 188 (7) 0.198 9 (2.7) 1 (0.5) 0.088 78 (10) 31 (6.2) 0.021
Table 1.  Comparisons of clinical and laboratory variables between the two COVID-19 pandemic waves, 
Aragon, Spain, February–September 2020. ICU: intensive care unit; IQR: interquartile range; NA: not 
applicable. Patients were grouped as hospitalized patients (total number of patients), admitted to the ICU, 
and deceased. Laboratory and clinical variables were baseline values and are presented as the median and 
interquartile range (IQR). Units are shown in parentheses. Values of sex, comorbidities and previous treatment 
are displayed as n and the percentage of total patients (%).
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C-reactive protein, LDH, and fibrinogen (Table 1). Other parameters of disease severity, such as neutrophilia and 
lymphopenia, indicated worse disease in patients infected in the first wave than those infected in the second wave.
Among patients admitted to the ICU, those in the first wave were significantly older (70 years [60–76] vs. 
62 years [54–72]) and had a higher rate of dementia compared to those admitted to the ICU in the second wave. 
Patients in the first wave also took antidiabetic drugs less frequently and exhibited higher levels of both clinical 
and analytical markers of serious illness compared to patients in the second wave (Table 1).
Unlike patients who were hospitalized or admitted to the ICU, patients who died in the first wave were 
younger than those who died in the second wave (85 years [77–90] vs. 87 years [81–91]; Table 1). Moreover, 
they were less obese in the first wave than in the second wave. Nevertheless, patients who died in the first wave 
had greater disease severity parameters than those who died in the second wave.
Mortality risk factors. The univariate analysis (Table 2) showed that mortality was best predicted in the 
first wave by urea (AUC = 0.81), age (AUC = 0.79), D-dimer (AUC = 0.73), and creatinine (AUC = 0.72). The best 
predictors of mortality in the second wave were age (AUC = 0.82), urea (AUC = 0.77), D-dimer (AUC = 0.71), 
and lymphocytes (AUC = 0.70).
The multivariate analysis (Table 3) showed that, in both pandemic waves, age (OR = 1.072), elevated tem-
perature (OR = 1.300), Urea (OR = 2.982), Potasisum (1.705), LDH (OR = 1.002), monocytes (OR = 2.231) and 
neutrophils (OR = 1.037) levels, malignancy (OR = 2.952), and taking vasodilators (OR = 3.490), potassium 
sparing diuretics (OR = 2.315), antipsychotics (OR = 3.247), antidepressants (OR = 1.593), antidementia drugs 
(OR = 2.125) and nutritional supplements (OR = 2.433) before hospitalization were independent risk factors 
associated with mortality. Conversely, normal oxygen saturation (OR = 0.949) and platelet levels (OR = 0.990) 
were protective factors.
Most of these factors shown no statistically significant between waves, we only found that monocytes 
(OR = 0.488) and taking potassium sparing (OR = 0.171) diuretics decreased their risk of mortality in the sec-
ond wave.
Longitudinal analysis. The cumulative incidence of ICU admission (Fig.  5) was significantly different 
between the two waves (p < 0.001). The probability of ICU admission ranged from 13% at 10 days to 16% at 
30 days during the first wave, and from 8% at 10 days to 10% at 30 days during the second wave. Stratifying by 
sex, the ICU admission probability among men was 16% to 20% during the first wave and 10% to 13% during 
the second wave (p < 0. 001). The probability of ICU admission was lower among women; it ranged from 10 to 
12% during the first wave and from 5 to 7% during the second wave (p < 0.001).
When stratified by age, we found that the need for ICU admission was significantly different between waves 
for the 0–60 years group (p = 0.05), the 60–80 years group (p < 0.001), and the > 80 years group (p < 0.001). For 
these three age groups, the rates of ICU admission were 13%-19%, 18%-25%, and 5%-7%, respectively, in the 
first wave, and 10%-15%, 14%-18%, and 1%-2%, respectively, in the second wave.
Overall survival was significantly different between waves (p = 0.007; Fig. 6). The probability of death ranged 
from 18% at 10 days to 37% at 30 days in the first wave, and from 11% at 10 days to 32% at 30 days in the second 
wave. In the first wave, mortality was greater for patients with either short or long hospitalizations. For men, 
mortality ranged from 16 to 38% in the first wave and from 10 to 32% in the second wave (p = 0.02). For women, 
mortality ranged from 19 to 36% in the first wave and from 11 to 32% in the second wave (p = 0.2). In both waves, 
mortality was greater among men than among women.
Mortality increased with age in both waves. However, overall survival was significantly different between 
waves in the 60–80 year group (p = 0. 02), but not in the 0–60 year or > 80 year groups (p = 0. 20). In the first 
wave, the probability of death at 10–30 days was 2%-7%, 13%-32%, and 30%-54% for hospitalized patients aged 
0–60 years, 60–80 years, and > 80 years, respectively. Notably, the probability of dying was lower in the youngest 
group than in the two older groups. Remarkably, the probability of death was higher for longer hospitalization 
periods, particularly among the oldest patients. In the second wave, the probability of death was 1%-5%, 5%-24%, 
and 21%-48% for the three age groups, respectively. These values were lower than those observed in the first 
wave, though the trends were similar.
Viral genome analysis. We analyzed 236 virus samples from the first wave and 56 from the second wave. 
The distribution of the D614G spike protein mutation was different between waves. It was present in 66% of 
viruses studied in the first wave and 100% of viruses studied in the second wave. According to the GISAID 
classification, 32% of the viruses analyzed during the first wave belonged to clades S (characterized by the L84S 
mutation in the NS8 protein) and V (with the G251V mutation in the NS3 protein), but these virus strains 
disappeared in the second wave. In contrast, 98.2% of viruses studied in the second wave belonged to clade G 
(characterized by the D614G spike protein mutation) and 1.8% belonged to clade GR (with the D614G spike 
protein mutation and the G204R mutation in the nucleocapsid protein).
Discussion
Aragon was one of the first regions in Europe to experience the emergence of the second pandemic wave of 
SARS-CoV-2 infection. This experience allowed early analyses and comparisons of the two waves, which could 
shed light on the future evolution of the pandemic.
Although the number of hospitalized patients was similar in both waves, we found significant differences 
in the increase in cases over time. The intensity of the first surge was very difficult for the healthcare system to 










p value adjustedAUC OR (95% CI) p value AUC OR (95% CI) p value
Univariant Model
Sex (Male: Female) 0.512 0.910 (0.789–1.05) 0.279 0.976 0.5 0.997 (0.846–1.174) 0.976 1.0
Age (years) 0.79 1.087 (1.08–1.095)  < 0.001  < 0.001 0.821 1.093 (1.085–1.102)  < 0.001  < 0.001
Emergency room
Systolic pressure (mmg Hg) 0.557 0.992 (0.988–0.995)  < 0.001 0.006 0.499 0.999 (0.995–1.003) n.s n.s
Diastolic pressure (mmHg) 0.595 0.977 (0.971–0.983)  < 0.001  < 0.001 0.584 0.974 (0.967–0.981)  < 0.001  < 0.001
Temperature (ºC) 0.504 1.015 (0.975–1.057) n.s n.s 0.543 1.032 (0.979–1.099) n.s n.s
Oxygen saturation (%) 0.609 0.905 0.888–0.921)  < 0.001  < 0.001 0.589 0.89 (0.868–0.913)  < 0.001  < 0.001
Capillary blood glucose (mg/dl) 0.614 1.006 (1.003–1.009)  < 0.001 0.017 0.656 1.003 (1.001–1.005) n.s n.s
Laboratory
Glucose (mg/dl) 0.603 1.006 (1.004–1.008)  < 0.001  < 0.001 0.6265 1.007 (1.005–1.009)  < 0.001  < 0.001
Creatinine (mg/dl) 0.716 2.353 (2.019–2.762)  < 0.001  < 0.001 0.696 2.36 (2.009–2.793)  < 0.001  < 0.001
Urea (g/l) 0.81 16.932 (12.12–24.01)  < 0.001  < 0.001 0.7676 8.396 (6.181–11.538)  < 0.001  < 0.001
Chloride (mmol/l) 0.602 1.069 (1.051–1.087)  < 0.001  < 0.001 0.5413 1.043 (1.0258–1.0607)  < 0.001 0.002
Potassium (mmol/l) 0.574 1.645 (1.365–1.986)  < 0.001 0.001 0.5275 1.235 (0.99–1.54) n.s n.s
Alanine aminotransferase (ALT) 
(U/l) 0.596 0.993 (0.989–0.996) 0.002 n.s 0.6151 0.993 (0.989–0.997) 0.005 n.s
Lactate dehydrogenase (LDH) (U/l) 0.589 1.002 (1.001–1.003)  < 0.001  < 0.001 0.5952 1.003 (1.002–1.004)  < 0.001  < 0.001
Prothrombin activity (APT) (%) 0.617 0.979 (0.974–0.984)  < 0.001  < 0.001 0.6071 0.982 (0.978–0.987)  < 0.001  < 0.001
International normalized ratio-
prothrombin time (INR-PT) 0.616 1.527 (1.314–1.82)  < 0.001 0.008 0.6047 1.398 (1.202–1.641)  < 0.001 0.016
Active partial thromboplastin time 
(RATIO-APTT) (seconds) 0.534 2.954 (1.839–4.792)  < 0.001 0.001 0.5115 1.403 (0.8801–2.190) n.s n.s
D-Dimer (microgr/l) 0.728 1 (1–1)  < 0.001 0.018 0.7127 1 (1–1.0001)  < 0.001 0.002
Leukocytes (mil/mm3) 0.632 1.136 (1.108–1.167)  < 0.001  < 0.001 0.5908 1.085 (1.061–1.111)  < 0.001  < 0.001
Lymphocytes (mil/mm3) 0.605 0.721 (0.608–0.846) 0.001 0.04 0.6626 0.392 (0.315–0.483)  < 0.001  < 0.001
Lymphocytes (%) 0.674 0.944 (0.933–0.955)  < 0.001  < 0.001 0.7002 0.926 (0.913–0.938)  < 0.001  < 0.001
Monocytes (mil/mm3) 0.518 1.653 (1.299–2.125)  < 0.001 0.029 0.4765 1.06 (0.835–1.302) n.s n.s
Monocytes (%) 0.596 0.95 (0.925–0.974)  < 0.001 0.032 0.6152 0.915 (0.887–0.943)  < 0.001  < 0.001
Neutrophils (mil/mm3) 0.647 1.157 (1.126–1.19)  < 0.001  < 0.001 0.6313 1.127 (1.099–1.157)  < 0.001  < 0.001
Neutrophils (%) 0.663 1.042 (1.034–1.052)  < 0.001  < 0.001 0.6899 1.059 (1.049–1.07)  < 0.001  < 0.001
Basophils (mil/mm3) 0.504 100.431 (2.111–4611.052) 0.048 n.s 0.5271 0.177 (0.003–6.835) n.s n.s
Basophils (%) 0.571 0.648 (0.445–0.923) n.s n.s 0.5874 0.380 (0.247–0.572)  < 0.001 0.008
Eosinophils (mil/mm3) 0.587 0.29 (0.058–1.288) n.s n.s 0.6072 0.062 (0.011–0.292) 0.0055 n.s
Eosinophils (%) 0.599 0.875 (0.78–0.972) 0.046 n.s 0.6178 0.717 (0.618–0.819)  < 0.001 0.005
Red blood cells (mill/mm3) 0.625 0.502 (0.427–0.588)  < 0.001  < 0.001 0.6034 0.569 (0.483–0.669)  < 0.001  < 0.001
Erythroblasts (mil/mm3) 0.538 666,455,985.639 (559.172–5875,529,981,928,593) 0.029 n.s 0.5306 1.422 (0.132–8.167) n.s n.s
Mean corpuscular hemoglobin 
concentration (MCHC) (g/dl) 0.641 0.564 (0.502–0.633)  < 0.001  < 0.001 0.6502 0.593 (0.53–0.662)  < 0.001  < 0.001
Hemoglobin (g/dl) 0.616 0.8 (0.757–0.846)  < 0.001  < 0.001 0.5796 0.866 (0.82–0.914)  < 0.001 0.001
Hematocrit (%) 0.588 0.946 (0.929–0.964)  < 0.001  < 0.001 0.5524 0.969 (0.951–0.988) 0.006 n.s
Mean corpuscular volume (MCV) 
(fl) 0.604 1.064 (1.046–1.083)  < 0.001  < 0.001 0.6277 1.073 (1.054–1.093)  < 0.001  < 0.001
Platelet count (mil/mm3) 0.565 0.997 (0.996–0.998)  < 0.001 0.003 0.596 0.996 (0.995–0.998)  < 0.001  < 0.001
Mean platelet volume (MPV) (fl) 0.566 1.213 (1.117–1.317)  < 0.001 0.005 0.5504 1.165 (1.066–1.273) 0.005 n.s
Interleukin-6 (pg/ml) 0.676 1.008 (1.005–1.012)  < 0.001 0.001 0.6659 1.004 (1.002–1.006)  < 0.001 0.013
C-reactive protein (mg/l) 0.625 1.045 (1.03–1.06)  < 0.001  < 0.001 0.6351 1.071 (1.051–1.091)  < 0.001  < 0.001
Procalcitonin (mg/l) 0.73 1.075 (1.029–1.135) 0.018 n.s 0.7363 1.318 (1.155–1.546) 0.002 n.s
Comorbidities
Malignancy 0.515 1.774 (1.311–2.391) 0.002 n.s 0.511 1.562 (1.091–2.2) 0.036 n.s
Vitamin B12 and folate deficiency 0.522 2.424 (1.773–3.318)  < 0.001  < 0.001 0.52 2.393 (1.666–3.4)  < 0.001 0.003
Iron-deficiency anemia 0.564 2.319 (1.94–2.772)  < 0.001  < 0.001 0.55 1.902 (1.558–2.316)  < 0.001  < 0.001
Hemostatic alterations 0.547 2.45 (1.977–3.037)  < 0.001  < 0.001 0.538 2.315 (1.789–2.981)  < 0.001  < 0.001
Eosinophilia 0.506 1.95 (1.18–3.203) 0.027 n.s 0.506 2.226 (1.171–4.069) 0.033 n.s
Asymptomatic hyperuricemia 0.518 1.22 (1.034–1.438) 0.048 n.s 0.509 1.103 (0.911–1.331) n.s n.s










p value adjustedAUC OR (95% CI) p value AUC OR (95% CI) p value
Acute pancreatitis 0.512 1.771 (1.258–2.483) 0.006 n.s 0.502 1.15 (0.723–1.767) n.s n.s
Ischemic cardiomyopathy 0.53 2.106 (1.648–2.688)  < 0.001  < 0.001 0.535 2.441 (1.852–3.2)  < 0.001  < 0.001
Heart failure 0.547 3.457 (2.679–4.474)  < 0.001  < 0.001 0.551 3.454 (2.645–4.498)  < 0.001  < 0.001
Atrial fibrillation 0.549 2.899 (2.302–3.656)  < 0.001  < 0.001 0.54 2.486 (1.919–3.205)  < 0.001  < 0.001
Pulmonary hypertension 0.505 3.7 (1.605–9.062) 0.012 n.s 0.501 2.806 (0.536–12.537) n.s n.s
Non rheumatic heart disease aortic 
stenosis 0.509 1.866 (1.23–2.817) 0.013 n.s 0.5 1.05 (0.562–1.836) n.s n.s
Atrial fibrillation 0.526 1.827 (1.439–2.316)  < 0.001 0.001 0.534 2.355 (1.788–3.082)  < 0.001  < 0.001
Hypertension 0.596 2.225 (1.918–2.586)  < 0.001  < 0.001 0.619 2.74 (2.297–3.277)  < 0.001  < 0.001
Stroke 0.562 3.075 (2.492–3.798)  < 0.001  < 0.001 0.573 3.881 (3.076–4.89)  < 0.001  < 0.001
Intermittent claudication 0.53 3.775 (2.709–5.303)  < 0.001  < 0.001 0.508 1.483 (0.983–2.187) n.s n.s
Cognitive impairment or dementia 0.585 3.653 (3.006–4.445)  < 0.001  < 0.001 0.589 4.36 (3.497–5.431)  < 0.001  < 0.001
Non-streptococcal tonsillitis 0.507 0.352 (0.158–0.69) 0.018 n.s 0.511 0.256 (0.097–0.549) 0.009 n.s
Acute bronchitis 0.539 1.638 (1.374–1.95)  < 0.001  < 0.001 0.545 1.742 (1.43–2.116)  < 0.001  < 0.001
Flu 0.524 0.213 (0.121–0.348)  < 0.001  < 0.001 0.517 0.338 (0.181–0.578) 0.002 n.s
Respiratory infections 0.512 1.72 (1.241–2.373) 0.006 n.s 0.511 1.617 (1.107–2.317) 0.032 n.s
Chronic obstructive pulmonary 
disease (COPD) 0.522 1.404 (1.155–1.704) 0.004 n.s 0.531 1.596 (1.284–1.974)  < 0.001 0.016
Obstructive sleep apnea 0.515 1.475 (1.142–1.897) 0.012 n.s 0.509 1.328 (0.967–1.798) n.s n.s
Obesity 0.516 0.768 (0.621–0.945) 0.039 n.s 0.505 1.082 (0.864–1.348) n.s n.s
Diabetes mellitus 0.545 1.744 (1.467–2.072)  < 0.001  < 0.001 0.546 1.64 (1.362–1.969)  < 0.001 0.001
Vitamin D deficiency 0.539 1.63 (1.369–1.939)  < 0.001  < 0.001 0.545 1.698 (1.401–2.054)  < 0.001  < 0.001
Gout 0.51 1.46 (1.076–1.97) 0.039 n.s 0.516 1.746 (1.255–2.398) 0.005 n.s
Hyperlipidemia 0.512 1.107 (0.959–1.277) n.s n.s 0.535 1.334 (1.131–1.572) 0.004 n.s
Previous treatments
Antiulcer drugs 0.625 2.794 (2.415–3.235)  < 0.001  < 0.001 0.614 2.578 (2.183–3.046)  < 0.001  < 0.001
Laxatives 0.51 2.054 (1.361–3.091) 0.004 n.s 0.514 3.456 (2.081–5.689)  < 0.001 0.002
Antidiabetic drugs 0.537 1.694 (1.406–2.038)  < 0.001  < 0.001 0.533 1.522 (1.243–1.857)  < 0.001 0.024
Vitamins: A, D, E 0.517 1.322 (1.078–1.616) 0.023 n.s 0.534 1.741 (1.389–2.17)  < 0.001 0.002
Calcium 0.517 1.576 (1.224–2.021) 0.003 n.s 0.518 1.779 (1.301–2.404) 0.002 n.s
Antithrombotic therapy 0.624 3.168 (2.719–3.693)  < 0.001  < 0.001 0.611 2.845 (2.395–3.378)  < 0.001  < 0.001
Oral iron 0.537 2.659 (2.06–3.436)  < 0.001  < 0.001 0.538 3.021 (2.256–4.027)  < 0.001  < 0.001
Vitamin B12 and folic acid 0.557 2.544 (2.082–3.109)  < 0.001  < 0.001 0.546 2.076 (1.666–2.578)  < 0.001  < 0.001
Digoxin and other cardiac glycosides 0.523 1.243 (1.066–1.448) 0.019 n.s 0.534 1.37 (1.152–1.627) 0.003 n.s
Vasodilators with venodilator action: 
nitroglycerin 0.523 3.952 (2.669–5.928)  < 0.001  < 0.001 0.521 2.816 (1.932–4.067)  < 0.001  < 0.001
Prostaglandins 0.503 1.873 (0.939–3.688) n.s n.s 0.506 1.974 (1.105–3.399) 0.045 n.s
Thiazide and thiazide-like diuretics 
(chlorthalidone) 0.507 2.054 (1.266–3.324) 0.014 n.s 0.507 2.056 (1.173–3.488) 0.029 n.s
Loop diuretic (furosemide, tora-
semide) 0.594 3.524 (2.936–4.234)  < 0.001  < 0.001 0.589 3.122 (2.565–3.794)  < 0.001  < 0.001
Potassium sparing diuretics 0.524 2.661 (1.938–3.661)  < 0.001  < 0.001 0.504 1.244 (0.799–1.88) n.s n.s
Chronic venous disease treatment 0.506 2.832 (1.458–5.597) 0.01 n.s 0.507 3.039 (1.501–5.997) 0.008 n.s
Varicose veins treatment 0.502 1.892 (0.735–4.761) n.s n.s 0.507 3.125 (1.591–6.004) 0.004 n.s
Beta-blockers 0.551 2.038 (1.693–2.451)  < 0.001  < 0.001 0.545 1.965 (1.587–2.425)  < 0.001  < 0.001
Dihydropyridine calcium channel 
blockers 0.521 1.611 (1.272–2.034)  < 0.001 0.031 0.534 2.044 (1.59–2.612)  < 0.001  < 0.001
Nondihydropyridine calcium chan-
nel blockers (verapamil, diltiazem) 0.511 2.611 (1.658–4.131)  < 0.001 0.02 0.509 2.359 (1.383–3.926) 0.007 n.s
Angiotensin-converting enzyme 
inhibitors 0.533 1.833 (1.482–2.264)  < 0.001  < 0.001 0.527 1.698 (1.327–2.157)  < 0.001 0.015
Angiotensin II receptor blockers 0.537 1.492 (1.267–1.754)  < 0.001 0.002 0.538 1.514 (1.256–1.82)  < 0.001 0.011
Medical treatment of benign pros-
tatic hyperplasia 0.55 2.561 (2.07–3.169)  < 0.001  < 0.001 0.535 2.054 (1.603–2.619)  < 0.001  < 0.001
Systemic glucocorticoids 0.51 1.807 (1.244–2.614) 0.009 n.s 0.512 2.31 (1.468–3.569) 0.002 n.s
Oral contraceptive 0.506 2.832 (1.458–5.597) 0.01 n.s 0.507 3.549 (1.721–7.21) 0.003 n.s
Pharmacologic urate-lowering 
therapy 0.537 2.39 (1.885–3.03)  < 0.001  < 0.001 0.527 1.977 (1.501–2.585)  < 0.001 0.002




Scientific Reports |        (2021) 11:18844  | https://doi.org/10.1038/s41598-021-98308-x
www.nature.com/scientificreports/
Another difference between the two waves was that the hospitalized patients were younger in the second 
wave than in the first wave. This difference was probably due to the greater exposure of younger people in the 
community in the second wave and the greater protection of older people, who were more concerned about the 
perils of the disease.
Compared to the first wave, the second wave had less marked clinical (high fever) and analytical (lympho-
penia, elevated D-dimer) predictors of worse  outcomes19,20. Moreover, age-related comorbidities, such as cer-
ebrovascular disease and dementia, were less prevalent in the second wave than in the first wave. Interestingly, 
diabetes was more prevalent in the second wave.
Patients transferred to the ICU had somewhat different characteristics between waves. Compared to the first 
wave, patients in the second wave were younger and more frequently took antidiabetic drugs. In addition, the 
frequency of cognitive impairment was lower in the second wave. It is likely that patients with these features 
were also infected in the first wave but the number was obscured by the larger number of older and seriously ill 
patients. Older and seriously ill patients were less numerous in the second wave than in the first wave. However, 
although patients who required hospitalization and ICU care were younger in the second wave than in the first 





p value adjustedAUC OR (95% CI) p value AUC OR (95% CI) p value
Analgesics 0.559 2.231 (1.861–2.675)  < 0.001  < 0.001 0.551 2.043 (1.66–2.507)  < 0.001  < 0.001
Antiepileptics 0.532 1.843 (1.487–2.283)  < 0.001  < 0.001 0.544 2.348 (1.845–2.975)  < 0.001  < 0.001
Antiparkinson drugs 0.52 3.221 (2.193–4.768)  < 0.001  < 0.001 0.518 3.331 (2.141–5.142)  < 0.001  < 0.001
Antipsychotics 0.563 3.28 (2.642–4.078)  < 0.001  < 0.001 0.564 3.419 (2.697–4.324)  < 0.001  < 0.001
Anxiolytics 0.552 2.035 (1.696–2.44)  < 0.001  < 0.001 0.53 1.519 (1.229–1.868) 0.001 0.043
Hypnotic therapy 0.53 2.028 (1.599–2.568)  < 0.001  < 0.001 0.543 2.699 (2.081–3.486)  < 0.001  < 0.001
Antidepressants 0.582 2.383 (2.028–2.801)  < 0.001  < 0.001 0.59 2.578 (2.153–3.085)  < 0.001  < 0.001
Psychostimulants 0.509 2.764 (1.611–4.789) 0.002 n.s 0.507 2.308 (1.277–4.042) 0.016 n.s
Antidementia drugs 0.535 2.821 (2.155–3.699)  < 0.001  < 0.001 0.549 4.024 (3.02–5.352)  < 0.001  < 0.001
Chronic obstructive pulmonary 
disease treatments 0.525 1.714 (1.362–2.152)  < 0.001 0.005 0.536 2.032 (1.592–2.578)  < 0.001  < 0.001
Antiglaucoma medications 0.526 1.991 (1.549–2.556)  < 0.001  < 0.001 0.525 1.968 (1.481–2.595)  < 0.001 0.004
Nutritional supplements 0.538 4.538 (3.29–6.321)  < 0.001  < 0.001 0.523 4.137 (2.713–6.3)  < 0.001  < 0.001
Table 2.  Univariate analysis of potential predictors of death in the two pandemic waves, Aragon, Spain, 
February–September, 2020. OR: Odds ratio; CI: confidence interval; n.s.: Not Significant. P value adjusted: 
adjusted p-values for multiple comparisons using the Holm method.




Interaction term (ref: 1st 
wave)
OR (95% CI) p-value OR (95%CI) p-value
Age (years) 1.072 (1.054–1.090)  < 0.001 0.999 (0.983–1.023) 0.939
Temperature (ºC) 1.300 (1.078–1.566) 0.006 0.943 (0.779–1.141) 0.546
Oxygen saturation (%) 0.949 (0.911–0.989) 0.013 1.044 (0.978–1.115) 0.191
Urea (g/l) 2.982 (1.741–5.109)  < 0.001 0.656 (0.308–1.439) 0.300
Potassium (mmol/l) 1.705 (1.250–2.326)  < 0.001 0.687 (0.431–1.095) 0.115
Alanine aminotransferase (ALT) (U/l) 0.990 (0.984–0.997) 0.003 1.004 (0.978–1.115) 0.366
Lactate dehydrogenase (LDH) (U/l) 1.002 (1.001–1.003) 0.004 1.001 (0.999–1.003) 0.224
Monocytes (mil/mm3) 2.231 (1.375–3.620) 0.001 0.488 (0.266–0.896) 0.021
Neutrophils (%) 1.037 (1.019–1.055)  < 0.001 0.994 (0.969–1.019) 0.642
Platelet count (mil/mm3) 0.995 (0.992–0.997)  < 0.001 1.001 (0.998–1.005) 0.322
Malignancy 2.952 (1.267–6.877) 0.012 0.667 (0.214–2.077) 0.485
Vasodilators 3.490 (1.290–9.405) 0.013 0.543 (0.141–2.085) 0.374
Potassium sparing diuretics 2.315 (1.109–4.832) 0.025 0.171 (0.048–0.605) 0.006
Antipsychotics 3.247 (1.281–8.231) 0.013 0.331 (0.087–1.261) 0.105
Antidepressants 1.593 (1.067–.2.378) 0.022 0.676 (0.370–1.235) 0.203
Antidementia drugs 2.125 (1.092–4.137) 0.026 0.480 (0.182–1.262) 0.136
Nutritional supplements 2.433 (1.063–5.569) 0.035 0.884 (0.231–3.388) 0.857
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Figure 5.  Cumulative incidence of ICU admissions for all patients (top), patients stratified by sex (middle), and 
patients stratified by age (bottom) in Aragon, Spain, February-September 2020. By sex: purple indicates men, 
green indicates women. By age: green indicates 0–60 years, red 60–80 years, and blue > 80 years. Solid lines: first 
wave; dashed lines: second wave. The p-values corresponds to the Gray test to compare survival curves between 
waves for groups stratified by sex or age.
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Figure 6.  Cumulative incidence of death for all patients (top), patients stratified by sex (middle), and patients 
stratified by age (bottom) in Aragon, Spain, February-September 2020. By sex: purple indicates men, green 
indicates women. By age: green indicates 0–60 years, red 60–80 years, and blue > 80 years. Solid lines: first wave; 
dashed lines: second wave. The p-values corresponds to the Gray test to compare survival curves between waves 
for groups stratified by sex or age.
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The most relevant finding in our study was that the overall 30-day mortality of hospitalized patients declined 
during the second wave. This significant decline in mortality affected essentially all patients aged 60 to 80 years 
old. A potential cause for this finding was that hospitalized patients had less severe parameters overall in the sec-
ond wave than in the first wave. These parameters included vital signs and the clinical inflammation markers that 
serve as prognostic factors for  severity21–23. Another explanation for the difference in mortality between waves 
could be improvements in the clinical management of patients. Although no antiviral drugs have clearly increased 
survival rates in patients with COVID-19, other advances in the management of patients with more severe 
infections have been associated with improved  outcomes24–26. In addition, unlike the rapid increase observed in 
the first wave, during the second wave, the number of cases increased gradually. Therefore, although the health 
system had been overloaded, health resource use increased gradually, which prevented a system collapse. As 
such, this situation may be associated with better outcomes.
Finally, we could not rule out the possibility that mutations in the virus may have reduced the virulence of 
SARS-CoV-2. We analyzed viral genomes from the first and second waves and found that the spike 614G muta-
tion, which was abundant only at the end of the first wave, was present in all genomes isolated in the second 
wave. These findings have been described throughout the  country27. Initially, this mutation was associated with 
greater disease  severity28. However, a recent study indicated that, although the G614 variant is related to greater 
infectivity and higher viral loads, there is no evidence that it is associated with disease  severity29.
This study has some limitations. In the first 2 months of the pandemic, there was a significant shortage of 
diagnostic tests. This situation prevented an overall comparison between pandemic waves. Due to these limita-
tions, we focused the comparison on patients admitted to the hospital. In this environment, there has never been 
a shortage of diagnostic tests. Other limitations of this study were primarily due to its retrospective nature and 
the data source (i.e., electronic medical records). Furthermore, this study included data from the entire region, 
and different hospitals may have employed different management criteria and different resource allocations. 
However, some of these limitations are compensated for by the high number of patients included.
In conclusion, patients in the first wave have worse clinical characteristics, and consequently the cumulative 
ICU admission and mortality were higher than those of the second wave. Regarding independent risk factor of 
mortality, they were similar in both waves, showing only differences in monocytes and potassium diuretics sav-
ers variables. Our study show differences between waves in our cohort and we can expect that vaccination also 
influence in the future for the trajectory of hospitalized patients by COVID-19 infection.
Data availability
The clinical and demographic data analyzed were retrieved through the BIGAN Gestion Clinica platform of the 
Aragón Department of Health, which contains the information from the Aragón Healthcare Records Database. 
Whole genome sequences of SARS-CoV-2 were retrieved from the database established by the global initiative 
on sharing all influenza data (GISAID).
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